Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors

COMMACK, N.Y., July 2, 2014 /PRNewswire/ -- It is a great honor for Avery Biomedical Devices, Inc. (ABD) to announce the appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark E Ginsburg, M.D., to its Board of Directors.

Dr. Ginsburg, with over 34 years of experience, is currently practicing at two facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg has been implanting the Avery Breathing Pacemaker since the late 1980's and is considered an expert in the implantation of the Avery System. In addition, he has travelled the world to implant the Avery System in those patients who are unable to travel to the United States. He has published numerous scientific papers and books such as Lung Volume Reduction Surgery (LVRS) and Emphysema Treatments. In addition, he was lead investigator on several clinical trials.

Martin Dobelle, CEO, states, "We are humbled to have Dr. Ginsburg join our Board of Directors. His experience and expertise will be invaluable to the future growth of ABD."

Dr. Ginsburg states, "It is a privilege to serve on the Board of Directors of ABD. This company has served the world's need in diaphragm pacing. Exciting new products are under development in this and related arenas as well. I look forward to providing medical and surgical input to the Board."

ABOUT ABD

Avery Biomedical Devices, Inc. is a privately-held company located on Long Island, New York. It manufactures the Avery Breathing Pacemaker System: an implanted diaphragmatic pacemaker which is used to free many quadriplegics, central sleep apnea and diaphragm paralysis patients from mechanical ventilation. Most patients strongly prefer pacing to mechanical ventilation for reasons such as breathing and speech patterns, ease of eating and drinking and improved sense of smell. Since breathing pacemakers costs far less than mechanical ventilation and do not use percutaneous wire that pass through the skin (infection risk), it is the more prudent choice for life support.

The Avery Breathing Pacemaker is the only device of its kind with premarket approval from the USFDA and CE marking privileges under the European Active Implantable Medical Device Directive. Should you know of a patient with quadriplegia, central sleep apnea, diaphragm paralysis or another condition that may benefit from an Avery Breathing Pacemaker, please contact us.

CONTACT:
Martin D. Dobelle, CEO
631-864-1600
www.averybiomedical.com

SOURCE Avery Biomedical Devices, Inc.

RELATED LINKS
http://www.averybiomedical.com/

reade more... Résuméabuiyad

Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors

Avanir Pharmaceuticals, Inc. (PRNewsFoto/Avanir Pharmaceuticals, Inc.)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr. Corrigan, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience.

Dr. Corrigan currently serves as president and chief executive officer of Zalicus Inc. a public biopharmaceutical company, a position he has held since January 2010. He has also served as a director of Zalicus and its progenitor companies since December 2006. Prior to Zalicus, Dr. Corrigan served as executive vice president, research and development at Sepracor, Inc. (now known as Sunovion Pharmaceuticals, Inc.). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, a pharmaceutical company acquired by Pfizer, Inc. in 2003, most recently as group vice president of Global Clinical Research and Experimental Medicine. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan has also been a member of the board of directors and audit committee of Cubist Pharmaceuticals, Inc. since June 2008. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and subsequently received specialty training in Psychiatry at Cornell and Maine Medical Center.

"It is a pleasure to welcome Mark to the Avanir Board," commented Craig Wheeler, chairman of the board, "Mark brings many years of experience in the healthcare sector combined with a deep knowledge of CNS research and development together with broad experience in guiding the growth of biopharma companies.  I look forward to the insights he will bring to our board and to working with him as Avanir pursues its growth initiatives."

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Joey Fleury, BrewLife
jfleury@brewlife.com
+1 (415) 946-1090

Logo - http://photos.prnewswire.com/prnh/20130207/LA55901LOGO

SOURCE Avanir Pharmaceuticals, Inc.

RELATED LINKS
www.avanir.com

reade more... Résuméabuiyad

CROS NT Ltd Announces Appointment of Andrew MacGarvey as CEO

LONDON, Dec. 12, 2013 /PRNewswire-iReach/ -- As part of the CROS NT Group global strategy, the company today announced the appointment of Andrew MacGarvey to the role of Chief Executive Officer and President from 1st January 2014. The move sees Paolo Morelli move into the role of Chairman for CROS NT allowing him to dedicate more time to PMH the holding company which oversees other life science businesses including ARITHMOS, its technology arm.

Paolo Morelli said, 'I am pleased to appoint Andrew as CEO of CROS NT, it is the culmination of a two-year plan. Andrew has overseen our expansion into the UK and USA and his combination of commercial and operational knowledge, alongside his passion for customer service, makes him the right candidate to take CROS NT forward. Andrew understands that we are a people business and I am confident he will continue to grow the company in a sustainable way. He has built a great team to support him and I look forward to watching them in the next phase of the CROS NT story.'

Morelli will devote more time to PMH, 'There are some great things happening within PMH and the time is right for me to dedicate more time to this project. I intend to work closely with ARITHMOS next year; the life sciences technology space has always excited me. Within ARITHMOS, we have the right portfolio of technologies and I want to make sure we are connecting with the market and getting these products to our customers'.

Andrew MacGarvey said 'It was a privilege to be asked to take on the role of CEO of CROS NT and I was delighted to accept the position. Paolo has built a company that reflects his philosophy. Every member of the team is highly valued, as are each and every one of our customers. My job is to continue to build the business, while ensuring we protect the unique way we work, and I am looking forward to the challenge. We are seeing growing demand for our offering, specialist statistical and data services delivered through a global organisation. Following our activities this year we are now able to deliver these services across the pharmaceutical, biotechnology and medical device sectors.'

MacGarvey brings over 15 years' experience in the sector to the role. He has worked at a number of CROs in senior positions covering both the commercial and operational areas. He has lived and worked in both the USA and the UK giving him an international perspective on the sector.

About CROS NT

In its 21st year, CROS NT is a global Contract Research Organization (CRO) specialized in clinical data services. With over 800 studies completed in a variety of therapeutic areas and indications, CROS NT has remained focused on biometrics including statistical consultancy, programming and analysis, clinical data management, medical writing, pharmacovigilance and life science technology solutions. We collect, integrate and analyze data from various sources and uses processes and technology to ensure excellent project governance, reporting and traceability. 

Media Contact: Mary Wieder, CROS NT Ltd, +44 (0)1908 488822, mary.wieder@crosnt.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE CROS NT

reade more... Résuméabuiyad